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Abstract: Fabry disease (FD) is a monogenic X-linked lysosomal storage disorder caused by a
deficiency in the lysosomal enzyme α-Galactosidase A (α-Gal A). It is a good candidate to be treated
with gene therapy, in which moderately low levels of enzyme activity should be sufficient for clinical
efficacy. In the present work we have evaluated the efficacy of a non-viral vector based on solid
lipid nanoparticles (SLN) to increase α-Gal A activity in an FD mouse model after intravenous
administration. The SLN-based vector incremented α-Gal A activity to about 10%, 15%, 20% and
14% of the levels of the wild-type in liver, spleen, heart and kidney, respectively. In addition, the
SLN-based vector significantly increased α-Gal A activity with respect to the naked pDNA used as a
control in plasma, heart and kidney. The administration of a dose per week for three weeks was more
effective than a single-dose administration. Administration of the SLN-based vector did not increase
liver transaminases, indicative of a lack of toxicity. Additional studies are necessary to optimize the
efficacy of the system; however, these results reinforce the potential of lipid-based nanocarriers to
treat FD by gene therapy.
Keywords: gene therapy; non-viral vectors; solid lipid nanoparticles; pDNA; Fabry disease; Fabry
mice; α-galactosidase A; intravenous administration
1. Introduction
Using genetic material to treat different diseases has been in the spotlight of therapeu-
tic approaches over the last few years. In 2003 the China Food and Drug Administration
(CFDA) approved the first gene therapy-based product (Gendicine™) to treat head and
neck carcinoma [1]. Since then, the number of clinical trials has increased steadily, resulting
in various gene therapy medical products (GTMPs) entering the market. To date, about
15 GTMPs, based on in vivo and ex vivo strategies, have been approved worldwide [2].
In addition, more than 3100 clinical trials with nucleic acids have been completed, are
ongoing or have been approved [3], with a future promising outlook.
Gene therapy offers a unique opportunity especially for the treatment of monogenic
diseases [4], which result from modifications in a single gene, such as Fabry disease (FD).
FD is an X-linked lysosomal storage disorder caused by mutations in the GLA gene, leading
to a deficiency in the lysosomal enzyme α-Galactosidase A (α-Gal A). As a result, gly-
cosphingolipids, predominantly globotriaosylceramide (Gb3) and its deacylated derivative
globotriaosylsphingosine (lyso-Gb3), accumulate systemically, particularly in vascular
endothelial and smooth muscle cells [5]. Current available treatment options for FD in-
clude intravenous (IV) enzyme replacement therapy (ERT) with two recombinant enzymes,
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agalsidase α (Replagal®) or agalsidase β (Fabrazyme®). However, ERT shows important
drawbacks: considerable clinic variation, the effect is determined by the initiation age, the
high cost, the formation of antibodies against the infused enzyme and the biweekly IV
administration frequency [6]. More recently, the approval of an oral chaperone, Migalastat®,
has increased therapeutic options for patients with FD. This small molecule reversibly
binds to the active site of specific mutant forms of endogenous α-Gal A, stabilizing it and
directing it to lysosomes. Nevertheless, Migalastat® is only effective in patients with certain
mutant forms of α-Gal A that are amenable to the treatment [7,8].
Different strategies have been proposed as an alternative to those treatments, such as
substrate reduction therapy, stem cell-based therapy, gene therapy and removal of storage
material [9,10]. FD is a great candidate to be treated by gene therapy, as it is caused by the
disruption of a single gene, clinical effect can be achieved with a 10% activity of normal lev-
els, it offers long-term therapeutic effects, reducing repeated administration necessity [11],
and in the case of non-viral gene therapy, it is cheaper than enzymatic therapy. At present,
several clinical studies are evaluating the safety of gene therapy for FD, which differ in
their therapeutic approaches [12]. The first multicenter, multinational, open-label study
(NCT03454893, NCT02800070; AVR-RD-01, AVROBIO) is based on ex vivo transduction of
hematopoietic stem cells with lentivirus. The aim of this approach is to transfect hematopoi-
etic stem cell-derived cells and use them as a production platform for functional α-Gal A
production, which will be secreted to the plasma and subsequently internalized by α-Gal
A-deficient cells. Other two clinical studies (NCT04046224, NCT04040049) are based on
adeno-associated viral vectors (AAV) for in vivo transduction of hepatocytes, using these
cells as an α-Gal A-secreting platform instead of hematopoietic stem cell-derived cells; one
of them (NCT04040049) is still in recruitment phase. A third clinical study on AAV-based
gene therapy is also in the recruitment phase and uses an attenuated AAV (4D-310; 4D
Molecular Therapeutics). Preclinical studies in mice demonstrated that the novel capsid
4D-C102 was especially efficient in transducing human cardiomyocytes.
Success of gene therapy depends largely on the delivery system used, which must
ensure protection of the genetic material against degradation, facilitating its internalization
and intracellular delivery into the target cells [13]. Considering the natural transduction
properties of most viruses, viral vectors have been at the forefront of gene delivery systems
for many years, and most of the approved GTMPs consist of viruses as gene delivery
vectors [2]. Nevertheless, the oncogenic and immunogenic potential related to the delivery
of viral vectors limit their use for gene therapy applications. Advances in material sciences
have prompted the development of safer delivery systems. Non-viral vectors are poorly
immunogenic and their production is simpler, cheaper and more reproducible. Moreover,
unlike viral vectors, non-viral systems are not limited by the molecular size of the gene to
be packaged. Their low transfection efficacy remains a challenge to be overcome, although
it has improved by different strategies [14,15].
Lipid-based systems are the most studied non-viral vectors at clinical level [3]. Among
them, lipid nanoparticles (LNs) show several advantages, such as low or absence of in vivo
toxicity, good long-term stability, production by economic and solvent-free techniques
and the possibility to autoclave and sterilize [16]. Even though most non-viral vectors
remain at pre-clinical and clinical level, LNs have taken a step forward with the approval
of Onpattro® (Patisiran). This GTMP is a short interfering RNA (siRNA) formulated in LNs
targeting the liver to reduce the levels of transthyretin; the Food and Drug Administration
(FDA) and the European Medicines Agency (EMA) approved it in 2018 for the treatment of
hereditary transthyretin amyloidosis [17]. More recently, some of the accepted vaccines
to defeat the SARS-CoV-2 contain messenger RNA (mRNA) encapsulated in LNs [18].
LNs have also been used as the delivery system of mRNA encoding α-Gal A, to target
hepatocytes. Once expressed, the α-Gal A was released to systemic circulation, and it
was able to reduce Gb3 and lyso-Gb3 levels in heart and kidney of mice and non-human
primates after repeated administration of the LNs (Moderna Inc and Translate Bio) [19,20].
Our research group has previously demonstrated the capacity of Solid Lipid Nanoparticles
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(SLNs) to transfect a plasmid DNA (pDNA) encoding a reporter protein (Green Fluorescent
Protein, GFP) in the liver after IV administration to mice [21,22].
The objective of the present work was to evaluate the ability of a SLN-based non-viral
vector carrying a pDNA encoding α-Gal A to increase in vivo enzyme activity levels in
plasma and tissues after IV administration to an α-Gal A knockout (KO) mouse model
of FD. Additionally, Aspartate Aminotransferase (AST) and Alanine Aminotransferase
(ALT) activity were measured in the liver of mice to assess the potential toxicity of the
SLN-based vector.
2. Materials and Methods
2.1. Materials
Precirol® ATO 5 (glyceryl palmitostearate) was kindly provided by Gattefossé (Madrid,
Spain). 1,2-Dioleoyl-3-trimethylammonium-propane chloride salt (DOTAP) was purchased
from Avanti Polar-lipids, Inc. (Alabaster, AL, USA). Tween 80 and dichloromethane were
obtained from Panreac (Madrid, Spain). D-(+)-Trehalose dihydrate, Protamine sulfate
salt from salmon (Grade X) (P), dextran (Mn of 3380 Da) (DX), 4-methylumbelliferyl-α-
D-galactopyranoside (4-MU-α-Gal), N-acetyl-D-galactosamine, 4-methylumbelliferone (4-
MU) and Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Activity
Assay Kits were obtained from Sigma-Aldrich (Madrid, Spain). Micro BCA™ Protein Assay
Kit was acquired from Thermo Fisher Scientific (Madrid, Spain). Plasmid pR-M10-αGal
A was purchased from Origene (Rockville, MD, USA). Other chemicals, if not specified,
were reagent grade from Sigma-Aldrich (Madrid, Spain) and Panreac (Barcelona, Spain).
Fabry mice (B6;129-Glatm1Kul/JAX stock #003535) [23] were purchased from The Jackson
Laboratory (Bar Harbor, ME, USA).
2.2. Preparation of SLNs and Vector
The SLNs were produced by a solvent emulsification–evaporation technique, pre-
viously described by del Pozo-Rodríguez et al. [24], with minor modifications. Briefly,
Precirol® ATO 5 was dissolved in dichloromethane (5% w/v), and then emulsified in an
aqueous phase containing DOTAP (0.4% w/v) and Tween 80 (0.1% w/v). The emulsion was
obtained by sonication (Branson Sonifier 250, Danbury, Connecticut, USA) for 30 s at 50 W.
The organic solvent was evaporated by stirring for 1 h and 45 min of vacuum. After the
evaporation of the organic solvent a suspension of SLNs was formed upon solidification
of the Precirol® ATO 5 in the aqueous medium. The SLNs were washed by centrifuga-
tion (3000 rpm, 20 min, 3× g) using Millipore (Madrid, Spain) Amicon® Ultra centrifugal
filters (NMWL: 100,000 Da). Finally, SLNs were lyophilized at −50 ◦C and 0.2 mbar for
42 h (LyoBeta 15, Telstar, Spain) in the presence of 5% (w/v) D-(+)-Trehalose dihydrate as
cryoprotectant.
To obtain the vector, first, an aqueous solution of protamine (P) was added to the
plasmid DNA (pDNA) pR-M10-αGal A to form P-pDNA complexes at w/w ratio of 2:1.
Then, an aqueous solution of dextran (DX) was incorporated at DX-P-pDNA ratios of 1:2:1
(w/w/w). Finally, lyophilized SLNs were resuspended with the suspension of DX-P-pDNA
complexes and incubated for 20 min at w/w/w/w ratio of 1:2:1:5. Electrostatic interactions
between negative and positive charges of the components led to the formation of the
final DX-P-pDNA-SLN vector, in which DX-P-pDNA complexes were adsorbed on the
surface of the SLNs. The final composition of the SLN-based vector is based on previous
studies [21,25–28], in which different vectors carrying pDNA encoding GFP or α-Gal A
were characterized in terms of encapsulation efficacy, capacity to bind, protect and release
the gene cargo, Transmission Electron Microscopy (TEM), stability, in vitro transfection
efficacy, cellular uptake and cell viability.
2.3. Characterization of the Vector: Size, Polydispersity Index and ζ Potential Measurements
The size and polydispersity index were determined by Dynamic Light Scattering
(DLS). ζ potential was measured by Laser Doppler Velocimetry (LDV). Samples were
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diluted in Milli-Q™ water (EDM Millipore, Billerica, MA, USA) and measurements were
carried out in a ZetaSizer Nano ZS (Malvern Instruments, Worcestershire, UK).
2.4. Animal Model
α-Gal A KO mice (B6;129-Glatm1Kul/JAX stock #003535) were used as FD model ani-
mals. α-Gal A KO mice were generated by replacing exon III and intron III of the GLA gene
with a neo cassette [23]. Breeding pairs were mated following the mating recommendations
from The Jackson Laboratory and their offspring were genotyped by the investigation
general services (SGIker) from the University of the Basque Country UPV/EHU following
the genotyping protocol from The Jackson Laboratory website. Animals were housed
under controlled temperature, humidity and 12 h light/dark cycles, with ad libitum access
to standard rodent chow and water.
2.5. Animal Experimentation
In vivo studies were approved by the Ethics Committee on Animal Experimen-
tation (CEEA) of the University of the Basque Country UPV/EHU (Permit number:
M20/2017/157; approval date: 14/06/2018) following the Spanish and European Union
(EU) laws and all the procedures were followed in accordance.
Procedures were conducted with ≈8-week-old male mice weighing between 20 and
28 g. Animals were divided into 8 different experimental groups (3–5 animals per group):
- Wild-type (+/0 for α-Gal A);
- Non-treated Fabry mice (−/0 for α-Gal A);
- Fabry mice treated with a single administration of the naked pDNA and sacrificed at
day 3;
- Fabry mice treated with a single administration of the naked pDNA and sacrificed at
day 7;
- Fabry mice treated with the multiple-dosage regimen of the naked pDNA and sacri-
ficed 7 days after the last administration;
- Fabry mice treated with a single administration of the SLN-based vector and sacrificed
at day 3;
- Fabry mice treated with a single administration of the SLN-based vector and sacrificed
at day 7;
- Fabry mice treated with the multiple-dosage regimen of the SLN-based vector and
sacrificed 7 days after the last administration.
Figure 1 features the experimental design of the administration and sampling protocol.
In order to avoid distress during experimental manipulation, mice were anesthetized
with 1–2% isoflurane (IsoFlo, Abbott, Madrid, Spain) in air, at a flow rate of 0.5–1 L/min.
Following the standard procedure, a unique dose of the naked pDNA and the SLN-based
vector was injected into the tail vein in a volume of 100 µL (60 µg of plasmid) for single-
dose studies. For multiple-dose studies, the same dose was injected once a week, for
3 weeks. The selection of the dose of pDNA was based on previous in vivo studies, where
protein expression was detected after the administration of SLNs containing 60 µg of pDNA
encoding GFP [21,22,29].
Three and seven days after the single administration, and 7 days after the last adminis-
tration for those receiving the multiple-dosage regimen, mice were humanely euthanatized
by cervical dislocation. Blood was collected by cardiac puncture on euthanized animals,
centrifuged at 5000 rpm at 4 ◦C for 8 min to obtain plasma, which was stored at −80 ◦C.
Heart, kidney, liver, spleen and brain were harvested from each mouse and stored at
−80 ◦C for analysis. Samples collected from wild-type mice and non-treated Fabry mice
were used as control.




Figure 1. Schematic representation of the experimental design of the administration and sampling 
protocol. * One dose per week for 3 weeks. α-Gal A: α-Galactosidase A; pDNA: plasmid DNA; 
SLN: solid lipid nanoparticle. 
2.6. α-Galactosidase A Activity Assay 
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conversion of 4-methylumbelliferyl-α-D-galactopyranoside (4-MU-α-Gal) into the prod-
uct 4-methylumbelliferone (4-MU). Tissues were homogenized by an MT-3K mini 
handheld homogenizer (Hangzhou Miu Instruments Co., Ltd., Hangzhou, China) and 
centrifuged at 12,000× g at 4 °C for 10 min. Supernatants were collected for the assay. 
Plasma samples were used directly. An aliquot of each sample was incubated with 4-MU-
α-Gal (5 mM) and N-acetyl-D-galactosamine (100 mM), a specific inhibitor of α-N-acetyl-
galactosaminidase (α-Galactosidase B), in 0.1 M sodium citrate buffer (pH = 4.4) at 37 °C 
under agitation for pre-determined periods of time, depending on the sample. The reac-
tion was stopped with 0.1 M glycine-NaOH buffer (pH = 10.4). The resultant 4-MU was 
determined by measurement of fluorescence (λexcitation = 360 nm; λemission = 450 nm). 
The protein concentrations were determined by the Micro BCA™ protein assay. One unit 
of α-Gal A activity is equivalent to the hydrolysis of 1 nmol of the substrate 4-MU-α-Gal 
in 1 h at 37 °C. α-Gal A activity was expressed as 4-MU nmol/h/mg total protein or 4-MU 
nmol/h/mL plasma. 
2.7. Liver Transaminase Activity Assay 
To assess the immunogenicity of the naked pDNA and SLN-based vector, the activity 
of Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) were meas-
ured in the liver homogenates of the mice by a colorimetric test, in accordance with the 
manufacturer’s instructions (Sigma-Aldrich, Madrid, Spain). 
2.8. Data Analysis and Statistics 
Normal distribution of data was assessed by Shapiro–Wilk test and homogeneity of 
variance by the Levene test. Student’s t-test was used to compare means from two inde-
pendent groups and ANOVA for multiple comparisons followed by Bonferroni or T3 
Dunnett post hoc, depending on the results of the Levene test of homogeneity of vari-
ances. p < 0.05 was considered statistically significant. All statistical computations were 
performed with IBM SPSS Statistics 26 (IBM Corp, Armonk, NY, USA). Data are shown as 
mean ± standard deviation (SD). 
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2.6. α-Galactosidase A Activity Assay
Enzymatic activity of α-Gal A was determined by a fluorimetric assay based on the
conversion of 4-methylumbelliferyl-α-D-galactopyranoside (4-MU-α-Gal) into the product
4-methylumbelliferone (4-MU). Tissues were homogenized by an MT-3K mini handheld
homogenizer (Hangzhou Miu Instruments Co., Ltd., Hangzhou, China) and centrifuged at
12,000× g at 4 ◦C for 10 min. Supernatants were collected for the assay. Plasma samples
were used directly. An aliquot of each sample was incubated with 4-MU-α-Gal (5 mM) and
N-acetyl-D-galactosamine (100 mM), a specific inhibitor of α-N-acetylgalactosaminidase
(α-Galactosidase B), in 0.1 M sodium citrate buffer (pH = 4.4) at 37 ◦C under agitation
for pre-determined periods of time, depending on the sample. The reaction was stopped
with 0.1 M glycine-NaOH buffer (pH = 10.4). The resultant 4-MU was determined by
measurement of fluorescence (λexcitation = 360 nm; λemission = 450 nm). The protein
concentrations were determined by the Micro BCA™ protein assay. One unit of α-Gal
A activity is equivalent to the hydrolysis of 1 nmol of the substrate 4-MU-α-Gal in 1 h
at 37 ◦C. α-Gal A activity was expressed as 4-MU nmol/h/mg total protein or 4-MU
nmol/h/mL plasma.
2.7. Liver Transaminase Activity Assay
To assess the immunogenicity of the naked pDNA and SLN-based vector, the activity
of Aspartate Aminotransfer s (AST) and Alanine Aminotransf r se (ALT) were mea-
sured in the liver homoge ates of the mice by colorimetric test, in accordance with the
manufacturer’s instructions (Sigma-Aldrich, Madrid, Spain).
2.8. Data Analysis and Statistics
Normal distribution of data was assessed by Shapiro–Wilk test and homogeneity
of variance by the Levene test. Student’s t-test was used to compare means from two
independent groups and ANOVA for multiple comparisons followed by Bonferroni or
T3 Dunnett post hoc, depending on the results of the Levene test of homogeneity of
variances. p < 0.05 was considered statistically significant. All statistical computations were
performed with IBM SPSS Statistics 26 (IBM Corp, Armonk, NY, USA). Data are shown as
mean ± standard deviation (SD).
3. Results
3.1. Characterization of the Vector: Size, Polydispersity Index and ζ Potential Measurements
The particle size of the vector was 233 ± 10.5 nm and it showed a polydispersity index
of 0.4 ± 0.02. The surface presented a positive charge of +43 ± 1.0 mV.
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3.2. α-Galactosidase A Activity Assay
Figure 2 represents the α-Gal A activity in different tissues of wild-type, non-treated
and treated Fabry mice with either the naked pDNA or the SLN-based vector. After a
single administration, the enzyme activity was measured at day 3 and 7. When animals
received three doses, the enzyme activity was measured 7 days after the last dose.
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Figure 2. α-Galactosidase A activity in plasma and tissues of wild-type, non-treated and treated
Fabry mice with the naked pDNA or the SLN-based vector, 3 and 7 days after a single dose and 7
days after the last administration of the multiple-dosage regimen. Data are expressed as mean ± SD
(n = 3–5 per group). * p < 0.05, ** p < 0.01, *** p < 0.001 with respect to the non-treated group; # p < 0.05,
## p < 0.01 between the naked pDNA and the SLN-based vector. Horizontal discontinuous lines
refer to 10% of the α-Galactosidase A activity of the wild-type. α-Gal A: α-Galactosidase A; WT:
wild-type; NT: non-treated; SD: single dose; MD: multiple doses; pDNA: plasmid DNA; SLN: solid
lipid nanoparticle.
Untreated Fabry mice showed significantly lower α-Gal A activity levels in plasma
and all tissues as compared to the wild-type. α-Gal A activity in plasma of Fabry mice
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was significantly higher in the animals treated with three doses of the SLN-based vector in
comparison to the animals treated with the naked pDNA. In liver, α-Gal A activity of mice
treated with the naked pDNA was significantly higher compared to non-treated Fabry
mice. Only when mice were treated with three doses of the SLN-based vector α-Gal A
activity was significantly higher than in non-treated animals. In spleen, 7 days after the
single administration and the multiple-dosage regimen of both the naked pDNA and the
SLN-based vector, enzyme activity significantly increased with respect to non-treated mice.
In heart, a significantly higher α-Gal A activity was only found when animals were treated
with three doses of the SLN-based vector. This increment also resulted in a significant
difference with respect to the administration of three doses of the naked pDNA. In kidney,
7 days after the administration of the SLN-based vector to FD mice, α-Gal A activity
was higher than in the non-treated group. Three doses of the vector produced a greater
increment of the enzyme activity compared to the naked pDNA. In heart and kidney,
the administration of the naked pDNA did not significantly increase the enzyme activity.
Neither the administration of the naked pDNA nor the administration of the SLN-based
vector induced any change of the α-Gal A activity in the brain of the animals.
3.3. Liver Transaminase Activity Assay
Figure 3 shows AST and ALT activity levels in the livers of mice. The administration
of the naked pDNA or the SLN-based vector did not significantly increase AST and ALT
activity, neither with a single injection nor with multiple doses.
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4. Discussion
Endogenous production of α-Gal A by gene therapy allows a hopeful perspective for
the treatment of FD. Even though recent studies with mRNA administered to animal mod-
els have shown promising results [19,20], pDNA may provide a much more sustained and
long-lasting gene expression. Other advantages of using pDNA versus mRNA include the
possibility to obtain abundant purified pDNA easily and economically, and the opportunity
to perform repeated administrations without triggering an immune response [30]. Never-
theless, pDNA transfection is more difficult than that of mRNA, mainly due to the nuclear
entry barrier [25]. In earlier studies, our research group has demonstrated the potential of
SLN-based vectors-mediated pDNA delivery encoding α-Gal A to produce the enzyme in
a liver-derived cell line (Hep G2) [26] and in a cell model of FD [27]. Herein, we report the
ability of the system to increase α-Gal A activity in plasma and different tissues after IV
administration to a mouse model of FD.
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The vector, prepared with DX, P, pDNA encoding α-Gal A (pR-M10-αGal A) and SLNs,
presents suitable characteristics for in vivo administration: particle size in the nanometer
range (233 ± 10.5 nm), and a positive surface charge (+43 ± 1.0 mV). In a previous work,
we showed that the DX-P-pDNA-SLN vector lacked of erythrocytes agglutination effect
and hemolytic activity [21]. Additionally, in the mentioned work, the vector bearing a
pDNA that encodes the intracellular reporter protein GFP was able to transfect the liver,
lung and spleen of mice after IV administration.
In order to know the capacity of the SLN-based vector to induce an increment in α-Gal
A activity in vivo, we administered it to GLA gene KO mice. In addition to the genotype
of Fabry mice, we also confirmed the phenotype in terms of α-Gal A activity levels as a
useful model to evaluate the efficacy of formulations to increase in vivo enzymatic activity.
The quantification of the α-Gal A activity in plasma and tissues of FD mice agreed with
those published by other researchers [19,20,30,31], and it was significantly lower than the
levels obtained in the same strain wild-type for GLA (Figure 2).
FD phenotypes are directly associated to the residual α-Gal A activity. In males, the classic
phenotype is the most severe due to low (<3%) α-Gal A activity; however, other mutations
present higher enzyme activity and cause late-onset or attenuated pathology [32]. In this sense,
restoring the enzyme activity to levels of healthy individuals does not seem necessary, and
clinical improvement can be obtained with a relatively small increment [33,34]; it has been
demonstrated that 10% enzyme activity of the wild-type is sufficient to totally clear deposit of
Gb3 in various organs [35]. Different studies have reported an efficient reduction of Gb3 and
lyso-Gb3 and maintenance of the reduced amount even after the α-Gal A levels fell [19,20,30].
We assessed the enzyme activity to ensure that the produced enzyme was functional.
After IV administration of the SLN-based vector to Fabry mice the α-Gal A activity
significantly increased in liver, spleen, heart and kidney with respect to non-treated mice.
It is known that nanoparticles greater than 200 nm in diameter, accumulate predominantly
in the liver and spleen [36]. In this sense, in a previous work carried out by our research
group [37], the IV administration of radiolabeled LNs formulated with Precirol® ATO 5
and Tween 80 to rats provided the highest radioactivity levels in kidney, liver and spleen.
The administration of three doses of the SLN-based vector augmented α-Gal A activity
in liver to levels about 10% of that of the wild-type, maybe due to the accumulation of
the vector and the subsequent sustained release of the pDNA. Moreover, administration
of the SLN-based vector resulted in an increase in α-Gal A activity that reached around
14% and 20% of the wild-type in kidney and heart, respectively; it is important to consider
that affectation of these organs is the major cause of morbidity and mortality in Fabry
patients [38–40]. In those tissues, enzyme activity incremented significantly above the
naked pDNA after multiple doses. The naked pDNA and the SLN-based vector produced
a significant increment of α-Gal A activity in spleen 7 days after both, single administration
and multiple doses. The spleen is one of the major organs responsible for filtering the blood
of foreign material [41], and previous investigations have demonstrated the high uptake of
nanocarriers by this tissue [42]. Nanoparticles are commonly scavenged by monocytes and
macrophages, which are part of the reticuloendothelial system and often accumulate in the
liver and spleen [42]. The transfection of these cells may justify the low levels in plasma
despite the enzyme activity levels observed in liver and spleen.
The naked pDNA was able to increase α-Gal A activity of Fabry mice not only in
spleen, but also in liver. Intravenously administered naked nucleic acids show very short
circulating half-life [43]. It has been shown that the liver is the main organ responsible
for the rapid clearance of systemically administered pDNA [44,45]. Therefore, the protein
expression observed in liver during the 7 days after the injection of the naked pDNA is
maybe due to a rapid removal from the bloodstream by this organ. Multiple administrations
of the naked pDNA did not lead to a higher activity level than that observed with a single
injection but remained approximately equal.
Accumulation of lipids in the liver can lead to hepatic toxicity [46] and activate
an immune response. Considering the α-Gal A activity detected in the liver after the
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administration of the naked pDNA and the SLN-based vector, indicative of the access to
this organ, we measured the activity of liver transaminases to assess the immunogenicity.
An increase in liver transaminases is indicative of liver injury, and AST and ALT are the
most widely used parameters [47,48]. Neither the naked pDNA nor the SLN-based vector
increased the activity of liver transaminases with respect to non-treated mice.
The increase of α-Gal A activity observed after IV administration to mice of either the
naked pDNA or the SLN-based vector, demonstrate their ability to circulate in the blood-
stream and reach the tissues. Contrary to the naked pDNA, the SLN-based vector provides
a higher stability to the pDNA and facilitates its internalization by the cells, which may
explain the higher efficacy [21,25–28]. After the administration of the SLN-based vector
once a week for three weeks, heart and kidney (the most important target organs) were the
tissues where the greatest difference in α-Gal A activity between the naked pDNA and the
SLN-based vector was detected. Furthermore, one of the major advantages of SLN-based
vectors is the versatility they offer to modify their surface [49]. Taking advantage of that
property, vectors could be formulated to direct the therapy by active targeting to organs
with major affectation. Thereby, depending on the phenotype and the most affected organs
in each patient, the treatment could be personalized and direct it to the desire site. Alterna-
tively, selective transfection of a specific tissue that could efficiently express α-Gal A can
be considered. Hydrolytic enzymes implicated in lysosomal storage disorders, including
α-Gal A, are secreted and can reach neighboring cells and distant tissues via systemic
circulation. Therefore, transfection of a certain organ can lead to a “cross-correction” phe-
nomenon [33]. In this regard, the liver is a highly specialized organ in protein production
that could act as α-Gal A factory to overexpress the enzyme, so that it is released to the
bloodstream to reach and correct distant tissues [26]. For hepatocyte-targeted therapy,
the particle size of the carrier is a key factor [50], and therefore, a smaller vector must be
developed. Furthermore, non-viral vectors can be directed to hepatocytes by incorporating
sugar ligands whose receptors are abundantly expressed in the surface of hepatocytes, such
as the asialoglycoprotein receptor, which effectively binds and internalizes oligosaccharides
and glycoproteins presenting D-galactose and N-acetyl-D-galactosamine moieties [51].
Brain affectation in FD involves manifestations that can vary in degree and extent, and
are mainly characterized by the development of white matter hyperintensities, stroke and
ischemia attacks [52]. Although nanocarriers have been proposed for targeting bioactives
to the brain [40], overcoming the blood–brain barrier (BBB) is still challenging. In our
study, we did not detect an increase of α-Gal A activity in brain, neither with the naked
pDNA nor with the SLN-based vector. The inability of the vector to cross the BBB may
probably explain the lack of effect in the brain. In addition, although circulating enzyme in
blood could reach other tissues, none of the existing recombinant enzymes available for
the treatment of FD has demonstrated the ability to reach this organ. Functionalization
of nanocarriers is helpful, if not necessary, to deliver bioactives to the brain. Insulin and
transferrin are usually employed as brain targeting moieties, because these proteins present
abundant receptors in BBB endothelial cells. Muntoni et al. [53] have recently developed
Methotrexate-loaded SLNs functionalized with insulin and transferrin by a PEGylated-
maleimide linker, and SLNs were successfully targeted towards the BBB in vivo in rats.
Hence, in order to promote the effect of our vector in the brain, decoration with the proteins
insulin or transferrin could be considered in future works.
Although reduction of Gb3 and lyso-Gb3 deposits should be confirmed, the SLN-
based vector was able to partially restore α-Gal A activity in some tissues. In a previous
study [20], the administration of the ERT recombinant α-Gal A to Fabry mice led to a very
rapid decrease in serum (no enzyme was observed in the sera 6 h after the IV injection).
In other studies of Fabry mice, IV administration of mRNA encapsulated in LNs increased
α-Gal A activity to supraphysiological levels. In one of these studies [20], the expression
of the enzyme decreased as soon as the mRNA was degraded, giving rise to the need
for repeated administrations to maintain reduced substrate levels. In another study [19],
α-Gal A activity was maintained up to 28 days after a single dose. pDNA-based non-
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viral gene therapy has not revealed relevant results so far [30,54], despite it presents
several advantages with respect to mRNA. In this regard, apart from the higher stability,
the persistence of pDNA in the nucleus as an episome may provide a long-lasting enzyme
expression, although optimization of the vector results essential for this purpose.
5. Conclusions
The results show the ability of SLN-based non-viral vectors to increase α-Gal A activity
in different organs, especially in liver, spleen, kidney and heart, after IV administration
to FD mice. The administration of a dose per week for three weeks was more effective
than a single-dose administration. Importantly, no liver toxicity was induced, allowing the
perspective of a liver-directed gene therapy. Although transfection efficacy of our vector
should be improved, this study is a proof of concept that shows its potential to treat FD by
gene therapy.
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